Formation of secondary allo-bile acids by novel enzymes from gut Firmicutes

Jae Won Lee\textsuperscript{a,b}, Elise S. Cowley\textsuperscript{c,d}, Patricia G. Wolf\textsuperscript{a,b,e,f,g}, Heidi L. Doden\textsuperscript{a,b}, Tsuyoshi Murai\textsuperscript{a}, Kelly Yovani Olivos Caicedo\textsuperscript{a}, Lindsey K. Ly\textsuperscript{a}, Furong Sun\textsuperscript{a}, Hajime Takei\textsuperscript{a}, Hiroshi Nittono\textsuperscript{a}, Steven L. Daniel\textsuperscript{a}, Isaac Cann\textsuperscript{b,i,m}, H. Rex Gaskins\textsuperscript{b,l,n}, Karthik Anantharaman\textsuperscript{a}, João M. P. Alves\textsuperscript{h}, and Jason M. Ridlon\textsuperscript{a,b,n,p}

\textsuperscript{a}Carl R. Woese Institute for Genomic Biology, University of Illinois Urbana-Champaign, Urbana, IL, USA; \textsuperscript{b}Department of Animal Sciences, University of Illinois Urbana-Champaign, Urbana, IL, USA; \textsuperscript{c}Department of Bacteriology, University of Wisconsin-Madison, Madison, WI, USA; \textsuperscript{d}Microbiology Doctoral Training Program, University of Wisconsin-Madison, Madison, WI, USA; \textsuperscript{e}Institute for Health Research and Policy, University of Illinois Chicago, Chicago, IL, USA; \textsuperscript{f}University of Illinois Cancer Center, University of Illinois Chicago, Chicago, IL, USA; \textsuperscript{g}School of Pharmaceutical Sciences, Health Sciences University of Hokkaido, Hokkaido, Japan; \textsuperscript{h}Department of Parasitology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil; \textsuperscript{i}Division of Nutritional Sciences, University of Illinois Urbana-Champaign, Urbana, IL, USA; \textsuperscript{j}Mass Spectrometry Laboratory, School of Chemical Sciences, University of Illinois Urbana-Champaign, IL, USA; \textsuperscript{k}Junshin Clinic Bile Acid Institute, Tokyo, Japan; \textsuperscript{l}Department of Biological Sciences, Eastern Illinois University, Charleston, IL, USA; \textsuperscript{m}Department of Microbiology, University of Illinois Urbana-Champaign, Urbana, IL, USA; \textsuperscript{n}Center for Advanced Study, University of Illinois Urbana-Champaign, Urbana, IL, USA; \textsuperscript{o}Department of Microbiology and Immunology, Virginia Commonwealth University, Richmond, VA, USA

ABSTRACT
The gut microbiome of vertebrates is capable of numerous biotransformations of bile acids, which are responsible for intestinal lipid digestion and function as key nutrient-signaling molecules. The human liver produces bile acids from cholesterol predominantly in the A/B-cis orientation in which the sterol rings are “kinked”, as well as small quantities of A/B-trans oriented “flat” stereoisomers known as “primary allo-bile acids”. While the complex multi-step bile acid 7α-dehydroxylation pathway has been widely studied for conversion of “kinked” primary bile acids such as cholic acid (CA) and chenodeoxycholic acid (CDCA) to deoxycholic acid (DCA) and lithocholic acid (LCA), respectively, the enzymatic basis for the formation of “flat” stereoisomers allo-deoxycholic acid (allo-DCA) and allo-lithocholic acid (allo-LCA) by Firmicutes has remained unsolved for three decades. Here, we present a novel mechanism by which Firmicutes generate the “flat” bile acids allo-DCA and allo-LCA. The BaiA1 was shown to catalyze the final reduction from 3-oxo-allo-DCA to allo-DCA and 3-oxo-allo-LCA to allo-LCA. Phylogenetic and metagenomic analyses of human stool samples indicate that BaiA and BaiA1 are encoded only in Firmicutes and differ from membrane-associated bile acid 3α-reductases recently reported in Bacteroidetes that indirectly generate allo-LCA from 3-oxo-Δ^5-LCA. We further map the distribution of baiP and baiA1 among Firmicutes in human metagenomes, demonstrating an increased abundance of the two genes in colorectal cancer (CRC) patients relative to healthy individuals.

Introduction
Bile acid synthesis in the liver represents a major route for removal of cholesterol from the body and bile acids function as an emulsifying agent for the digestion of lipid-soluble dietary components in the aqueous lumen of the small bowel.\textsuperscript{1} In humans, the liver synthesizes two abundant primary bile acids, cholic acid (CA; 3α,7α,12α-trihydroxy-5β-cholan-24-oic acid) and chenodeoxycholic acid (CDCA; 3α,7α-dihydroxy-5β-cholan-24-oic acid) from cholesterol. Before active secretion from the liver, bile acids are conjugated to either taurine or glycine at the C-24 carboxyl group.\textsuperscript{1} When bile acids reach the terminal ileum, they are actively transported across the epithelium into portal blood and returned to the liver in a process known as enterohepatic circulation (EHC). Daily, several hundred milligrams of bile acids escape EHC and enter the large intestine. Colonic bacteria are capable of carrying out numerous biotransformations of primary bile acids to diverse secondary bile acids in the large intestine. The composition of intestinal and fecal bile acids in germ-free animals reflects the biliary composition.\textsuperscript{2–5} Meanwhile, in conventional animals with a normal gut microbiota, fecal
bile acid composition is diversified from only a few primary bile acids synthesized by the host to an estimated ~400 secondary bile acid products. Bacterial modifications to bile acids provide a form of interdomain communication given that beyond mere lipid-digesting detergents, bile acids are important nutrient-signaling molecules. Indeed, microbial metabolism of bile acids is widely recognized to contribute to numerous human disorders including, but not limited to, cancers of the liver and colon, obesity, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD), cholelithiasis, diabetes, and dysbiosis. Meanwhile, bile acids can affect the physiology of the colon, promote malignancies, increase fecal bile acid excretion, and, thereby, influence the gut microbiota. In this context, bile acids are considered key metabolites in the gut, which provide an opportunity for the development of new strategies in the prevention and treatment of various diseases such as cancer, liver disease, and colorectal diseases.}

A myriad of microbial bile acid biotransformations occur in the large intestine and include two key transformations. First, the conjugated bile acids are hydrolyzed to unconjugated bile acids and glycine or taurine by bile salt hydrolase (BSH). Second, the unconjugated primary bile acids CA and CDCA are converted to deoxycholic acid (DCA; 3a,12a-dihydroxy-5β-cholan-24-oic acid) and lithocholic acid (LCA; 3a-hydroxy-5β-cholan-24-oic acid) via 7a-dehydroxylase, respectively. BSH (EC 3.5.1.24) enzymes are widely distributed among predominant microbial phyla within the domains Bacteria and Archaea inhabiting the human GI tract and catalyze the substrate-limiting deconjugation of bile acid amides. The resulting major secondary bile acids routinely measured in human fecal samples are unconjugated derivatives of DCA and LCA. A bile acid inducible (bai) regulon encoding enzymes involved in the conversion of CA to DCA (Figure 1), and CDCA and ursodeoxycholic acid (UDCA; 3a,7β-dihydroxy-5β-cholan-24-oic acid) to LCA has been elucidated over the past three decades in strains of Lachnolocostium scindens (formerly Clostridium scindens), Peptacetobacter hiranonis (formerly Clostridium hiranonis), and Lachnolocostium hylemonae (formerly Clostridium hylemonae). Discovery and characterization of bai genes have allowed recent studies to extend the species distribution of 7-dehydroxylating bacteria into new families within the Firmicutes through bioinformatics-based searches of metagenomic sequence databases. Similarly, comparison of the distribution of bai genes between fecal metagenomes obtained from healthy and disease cohorts has also enabled the association of the abundance of bai genes with risk for adenomatous polyps or colorectal cancer. This agrees with bile acid metabolomic studies that demonstrate increased fecal and serum DCA and LCA derivatives in subjects at high risk for CRC. Conversely, lower abundance of bai genes is associated with bile acid dysbiosis characterized by increased fecal conjugated primary bile acids in inflammatory bowel diseases.

There are additional bai genes yet to be accounted for in strains of L. scindens that result in the formation of stereoisomers of DCA and LCA known as “secondary allo-bile acids”. In 1991, Hylemon et al. reported that allo-deoxycholic acid (allo-DCA; 3a,12a-dihydroxy-5β-cholen-24-oic acid) formation is a C4-inducible side-product of bile acid 7-dehydroxylation by L. scindens. During the conversion of cholesterol to the primary bile acids CA and CDCA, the liver enzyme Δ4,3ketosteroid-5β-reductase (3-oxo-Δ4-stereoid-5β-reductase; AKR1D1) saturates the Δ4, bond generating steroid A/B rings in the cis-orientation which appear “kinked” (Figure 1). When CA is transported into bacteria expressing bai genes, the first oxidative steps of bile 7-dehydroxylolation, catalyzed by BaiA and BaiCD, “resetting” A/B ring stereochemistry through formation of the 3-keto-Δ4 structure. This is followed by the rate-limiting 7α-dehydration (BaiE). The BaiCD was shown to then re-establish stereochemistry by catalyzing the conversion of 3-oxo-Δ4-DCA (12α-hydroxy-3-oxo-5β-chol-4-en-24-oic acid) to 3-oxo-DCA (12α-hydroxy-3-oxo-5β-cholan-24-oic acid), which is further reduced by BaiA1 and BaiA2 to DCA. The current model of bile acid 7α-dehydroxylation suggests that another enzyme, currently unknown, acts on 3-oxo-Δ4-DCA to form the alternative stereoisomer, 3-oxo-allo-DCA (12α-hydroxy-3-oxo-5β-cholan-24-oic acid), which is reduced by another unknown reductase to allo-DCA. Secondary allo-bile acids have a “flat” shape owing to hydrogenation that results in an A/B-trans orientation (Figure 1). While few studies have reported measurement of allo-DCA and allo-LCA (3-oxo-5β-cholan-24-oic acid), two studies have shown these bile acids are enriched in the feces of patients with CRC. Derivatives of allo-LCA are
also reported to be enriched in Japanese centenarians, although there is a paucity of measurement of secondary allo-bile acids across populations and disease states. Thus, determining the gene(s) encoding reductases in *L. scindens* and other gut microbes responsible for the formation of allo-DCA and allo-LCA is of biomedical importance.

We recently reported genome-wide transcriptome profiling of *L. scindens* ATCC 35704 in the presence of CA and DCA and identified a potential candidate bile acid-inducible 3-oxo-Δ⁴-5α-reductase. Here, we confirm that this candidate bile acid-inducible gene encodes a novel bile acid 3-oxo-Δ⁴-5α-reductase responsible for secondary allo-bile acids formation. We have named this gene in *L. scindens* ATCC 35704 the *baiP* gene. We previously reported identification of the *baiJ* gene as part of a polycistronic operon in *L. scindens* VPI 12708 and *L. hylemonae* DSM 15053, whose function remained unknown. Our current study reports that the *baiJ* gene also encodes a bile acid 3-oxo-Δ¹-5α-reductase. The *baiP* and *baiJ* genes are distributed solely among the Firmicutes. Identification of these *bai* genes may provide the
ability to predict and potentiate the formation of alternative forms of secondary bile acids whose ring structures are “flat” rather than the “kinked” form produced by the host. Indeed, we developed Hidden Markov Models (HMMs) of bai proteins and determined the distribution of baiP and baiJ in human metagenomes, demonstrating increased abundance in colorectal cancer (CRC) patients relative to healthy individuals.

Results

The HDCHBGLK_03451 gene from L. scindens ATCC 35704 encodes a bile acid 5α-reductase, yielding secondary allo-bile acids

Prior work established that allo-DCA is a CA-induced side-product of CA metabolism in cell-extracts of L. scindens VPI 12708 (Figure 1). We previously identified L. scindens ATCC 35704 gene HDCHBGLK_03451 as CA-inducible and suggested

Figure 2. The baiP gene from L. scindens ATCC 35704 encodes a bile acid 5α-reductase. (a) Formation of bile acid stereoisomers after reduction of 3-oxo-Δ4-LCA and 3-oxo-Δ4-DCA by 5α-reductase. (b) Gene organization of baiP with genomic context and domain structure of BaiP. (c) Cloning strategy for heterologous expression of N-terminal his-tagged recombinant BaiP in E. coli BL21(DE3). SDS-PAGE confirms expression of 60.5 kDa recombinant BaiP. (d) Representative LC/MS chromatograms after resting cell assay with E. coli BL21(DE3) pETduet_Control or pETduet_BaiP incubated in anaerobic PBS containing 50 μM 3-oxo-Δ4-LCA (Top panels 1 & 2) or 50 μM 3-oxo-Δ4-DCA (Bottom panels 3 & 4). Standards are shown in Panel 5 (bottom). (e) Time course of 3-oxo-allo-LCA production by the E. coli BL21(DE3) pETduet_BaiP strain. Data points indicate the mean concentration of 3-oxo-allo-LCA ± SD (three biological replicates).
this is a likely candidate for bile acid 5α-reductase\(^3\) (Figure 2a). The gene HDCHBGLK_03451 encodes a 563 amino acid protein comprising FMN (flavin mononucleotide) and FAD (flavin adenine dinucleotide)-binding domains (Figure 2b). The HDCHBGLK_03451 gene from L. scindens ATCC 35704 was codon-optimized for E. coli and over-expressed in E. coli (Figure 2c) for resting cell assays with bile acid intermediates (Figure 2d). The stereo-chemistry of the A/B ring junction is lost during the steps leading up to and following 7α-dehydration of CA (BaiE), resulting in formation of a 7α-deoxy-3-oxo-Δ\(^4\)-intermediates of DCA or LCA, respectively, which are reduced by the BaiH yielding 3-oxo-Δ\(^4\)-intermediates.\(^3\) The 3-oxo-Δ\(^4\) intermediate is then predicted to yield either 3-oxo-DCA (BaiCD) or 3-oxo-allo-DCA (BaiP). The same enzymatic steps are involved in the conversion of CDCA to 3-oxo-Δ\(^4\)-LCA followed by conversion to 3-oxo-LCA (3-oxo-5α-cholan-24-oic acid) or 3-oxo-alloLCA (3-oxo-5α-cholan-24-oic acid) by BaiCD or BaiP, respectively (Figure 1).

We therefore chemically synthesized 3-oxo-Δ\(^4\)-DCA and 3-oxo-Δ\(^4\)-LCA and incubated these substrates (50 μM) with E. coli expressing HDCHBGLK_03451 under anaerobic conditions in PBS. When 3-oxo-Δ\(^4\)-LCA was present as the substrate, 3-oxo-alo-LCA (RT = 2.30 min; m/z = 373.3) was synthesized, but not 3-oxo-LCA (RT = 2.50 min; m/z = 373.3) (Figure 2d). The 6 h reaction yielded 7.00 ± 0.46 μM 3-oxo-alo-LCA (Figure 2e). Similarly, incubation of resting cells with 3-oxo-Δ\(^4\)-DCA yielded a product (RT = 1.08 min; m/z = 389.26) consistent with 3-oxo-alo-DCA (RT = 1.08 min; m/z = 389.26), but not 3-oxo-DCA (RT = 1.20 min; m/z = 389.26) (Figure 2d). These data confirm that HDCHBGLK_03451 encodes a novel bile acid 5α-reductase, and we propose the name baiP for this gene (See Supplementary material, Figure S1).

We previously reported a cortisol-inducible operon (\(desABCD\)) in L. scindens ATCC 35704 encoding steroid-17,20-desmolase (\(DesAB\)) and NADH-dependent steroid 20α-hydroxysteroid dehydrogenase (\(DesC\)).\(^4\) \(DesC\) reversibly forms cortisol and 20α-dihydrocortisol,\(^4\) and \(DesAB\) catalyzes the side-chain cleavage of cortisol yielding 11β-hydroxyandrostenedione (11β-OHAD).\(^4\) Because substrates and products in the desmolase pathway have 3-oxo-Δ\(^4\)-structures analogous to 3-oxo-Δ\(^4\)-DCA and 3-oxo-Δ\(^4\)-LCA, we next performed resting cell assays with E. coli strain expressing the BaiP enzyme. LC/MS analysis of reaction products indicates that cortisol and 11β-OHAD were not substrates for BaiP (Figure S2).

**Phylogenetic analysis of BaiP followed by functional assay reveals the baiJ gene also encodes bile acid 5α-reductase**

Having provided experimental evidence that baiP encodes an enzyme with bile acid 5α-reductase activity, we wanted to determine the phylogeny of the BaiP from L. scindens ATCC 35704. A subtree of the >1,400 sequences representing close relatives of the BaiP from L. scindens ATCC 35704 was generated (Figure 3a). The proteins most closely related to BaiP from L. scindens ATCC 35704 in the “BaiP Cluster” were from Lachnocolastridium strains MSK.5.24, GGCC_0168, and Lachnospiraceae bacterium 5_1_57FAA. Additional FAD-dependent oxidoreductase BaiP candidates from a penguin isolate, Proteocatella sphenisci DSM 23131 (76% sequence identity), and P. hiranonis\(^15\)\(^44\) (72% sequence identity) were also identified at high bootstrap values (90–100%). Previous work established bai genes in P. hiranonis,\(^45\) although the present data provide first indication that P. hiranonis has the potential to form secondary allo-bile acids (Figure 3a, 3b). P. sphenisci has also been reported to encode the bai polycistrionic operon,\(^2\)\(^1\)\(^2\) and our demonstration that P. sphenisci harbors baiP indicate that secondary allo-bile acids may constitute part of the bile acid metabolome of penguin guano (Figure 3b).

A second closest FAD-dependent oxidoreductase cluster (~45% ID) to BaiP from L. scindens ATCC 35704 was composed of the previously named BaiJ proteins from L. scindens VPI 12708, L. hylemonae DSM 15053, and P. hiranonis DSM13275, as well as Dorea sp. D27, and an unclassified Clostridium sp. (“BaiJ Cluster”). Prior work established a novel bai operon in which the baiJ gene is adjacent to the baiK gene on a polycistrionic operon in L. scindens VPI 12708 and L. hylemonae DSM 15053.\(^40\) Evidence was also presented that L. scindens VPI 12708 and L. hylemonae DSM 15053 formed allo-DCA.\(^46\) It was then reported that the BaiK is a paralog of
Figure 3. Large scale phylogenetic analysis of BaiP from L. scindens ATCC 35704 reveals baiJ gene from C. scindens VPI 12708 encodes a bile acid 5α-reductase. (a) Maximum-likelihood tree of >2,300 protein sequences from NCBI’s non-redundant database that were similar to BaiP from L. scindens. The subtree containing BaiP from L. scindens formed two clusters containing BaiP sequences (Purple) from other Firmicutes known to convert CA to DCA. The second cluster contains BaiJ proteins, representing several strains known to convert CA to DCA. (b) Arrangement of genes in the bile acid inducible (bai) operon in various species of bile acid 7α-dehydroxylation gut bacteria. The gene encoding enzymes carrying out bile acid metabolism in gut bacteria capable of producing secondary allo-bile acids. Biochemical pathway leading to secondary allo-bile acid formation is shown in Figure 1. (c) Cloning strategy for baiJ gene from L. scindens VPI 12708 and SDS-PAGE after purification of recombinant His-tagged BaiJ. (d) Representative LC/MS chromatographs after resting cell assay with E. coli BL21(DE3) pETduet_Control or pETduet_BaiJ incubated in anaerobic PBS containing 50 μM 3-oxo-Δ5-LCA (Top panels 1 & 2) compared to pETduet_BaiP (Panel 3). Panels 4 & 5 display chromatograms of reaction products formed after incubation of E. coli BL21(DE3) pETduet_Control or pETduet_BaiJ incubated in anaerobic PBS containing 50 μM 3-oxo-Δ5-DCA compared to pETduet_BaiP (Panel 6). Standards are shown in Panel 7 (bottom). (e) Time course of 3-oxo-allo-LCA production by the E. coli BL21(DE3) pETduet_BaiJ strain. Data points indicate the mean concentration of 3-oxo-allo-LCA ± SD (two biological replicates).
BaiF in *L. scindens* VPI 12708, and both proteins catalyze bile acid coenzyme A transferase from the end-product secondary bile acids, DCA~SCoA and allo-DCA~SCoA, to primary bile acids including CA, CDCA, allo-CA, and UDCA. The *baiJ* gene has been shown previously to be enriched in the gut microbiome in mouse models of liver cancer and CRC, diseases reported to be enriched in secondary allo-bile acids in the biliary pool in the few studies that have measured them. Taken together, the close phylogenetic clustering of BaiJ with BaiP indicates that the *baiJ* gene may also encode a bile acid 5α-reductase isoform (Figure 3a, 3b). To test this hypothesis, we cloned and overexpressed the *baiJ* gene from *L. scindens* VPI 12708 (accession number: ACF20978) in *E. coli* BL21(DE3) (Figure 3c), and measured conversion of 3-oxo-Δ⁴-LCA and 3-oxo-Δ⁴-DCA in resting cell assays (Figure 3d). When 3-oxo-Δ⁴-LCA (RT = 1.60; *m/z* = 371.25) was the substrate, a product eluting at the same position as 3-oxo-allo-LCA (RT = 2.29; *m/z* = 373.27), but not as 3-oxo-LCA (RT = 2.45; *m/z* = 373.26), was observed. An anaerobic resting cell assay (6 h) resulted in the formation of 4.4 ± 0.54 μM 3-oxo-allo-LCA (Figure 3e). Similarly, when 3-oxo-Δ⁴-DCA (RT = 0.90; *m/z* = 387.25) was the substrate,
a product that eluted at the same position as 3-oxo-allo-DCA (RT = 1.08; m/z = 389.26), and different from 3-oxo-DCA (RT = 1.20; m/z = 389.27), was observed (Figure 3d). These results establish a function for the baiP gene product and indicate that strains of L. scindens and other bile acid 7α-dehydroxylating bacteria encode distinct bile acid 5α-reductase isoforms.

**BaiP and BaiA1 catalyze consecutive final reductive steps in the formation of allo-DCA and allo-LCA**

Having established that BaiP converts 3-oxo-Δ⁴-LCA to 3-oxo-allo-LCA, we next sought to identify an enzyme from L. scindens ATCC 35704 catalyzing the final reductive step from 3-oxo-allo-LCA to allo-LCA. There is compelling evidence that BaiA1 and BaiA2 enzymes catalyze the first oxidative and last reductive steps in the pathway. This comes from substrate-specificity and kinetic analyses of BaiA1 and BaiA2 showing that 3-oxo-DCA and 3-oxo-LCA are substrates and by the observation that BaiA is sufficient for the final reductive step yielding DCA. Prior work established that the baiA genes encode bile acid 3α-hydroxysteroid dehydrogenase (3α-HSDH) that catalyze the first oxidation step, formation of 3-oxo-7α-hydroxy-5β-bile acids, and the final reductive step generating 7-deoxy-3α-hydroxy-5β-bile acids. However, the ability of BaiA enzymes to recognize allo-bile acids has not been established (Figure 4a). The baiA1 gene from L. scindens ATCC 35704 was codon-optimized for *E. coli* and overexpressed in *E. coli* alone or in combination with baiP (Figure 4b). Whole cell *E. coli* assays with overexpressed BaiA1 converted 3-oxo-allo-LCA (RT = 2.30 min; m/z = 373.2) to a product consistent with allo-LCA (RT = 2.74 min; m/z = 375.3), but not LCA (RT = 2.68 min; m/z = 375.3). *E. coli* expressing both BaiP and BaiA1 converted 3-oxo-Δ⁴-LCA (RT = 1.65 min; m/z = 371.3) to allo-LCA (RT = 2.74 min; m/z = 375.3) and 3-oxo-Δ⁴-DCA (RT = 0.75 min; m/z = 387.3) to allo-DCA (RT = 1.51 min; m/z = 391.3) confirming the role of BaiP and BaiA1 in the cooperative catalysis of the two final steps in formation of secondary allo-bile acids (Figure 4c).

A previous bioinformatics study hypothesized based on gene context and annotation that CLOSCI_00522, a gene directly downstream from
baiN (CLOSCL_00523), encodes a predicted NAD(FAD)-utilizing dehydrogenase involved in the final reductive step\textsuperscript{31}. (Figure S1). This gene was named “baiO”.\textsuperscript{31} An organism may encode several proteins from different lineages that have similar catalytic activity. Indeed, the BaiN\textsuperscript{50} is predicted to catalyze similar sequential reactions to BaiH and BaiCD.\textsuperscript{35} We therefore tested the hypothesis that the previously annotated baiO encodes either a bile acid 3-oxo-Δ\textsuperscript{4}-reductase and/or bile acid 3α-HSDH. We cloned the baiO in pETduet and verified the expression after His-tag purification and SDS-PAGE (Figure S1a, S1b). Analysis of bile acid products after 24 h incubation of E. coli expressing BaiO enzyme in a resting cell assay with either 3-oxo-LCA, 3-oxo-DCA (Figure S1c, S1d), 3-oxo-Δ\textsuperscript{4}-LCA, or 3-oxo-Δ\textsuperscript{4}-DCA (Figure S1e, S1f), did not yield a detectable product by LC/MS. While this does not disprove that CLOSCL_00522 is involved in bile acid metabolism, we were not able to confirm its function.

**The distribution of baiP and baiJ genes in public human metagenome datasets**

Having shown that BaiP clusters with the previously identified BaiJ from *L. hylemonae* DSM 15053, the next objective was to determine the presence of bai genes involved in bile acid 7-dehydroxylation among bacterial genomes from human stool samples. We utilized reference sequences of BaiP and BaiJ as well as BaiE and BaiCD (Figure 5a) to generate HMMs in order to search public human metagenomic databases. We expected that the occurrence of BaiE and BaiCD which are co-transcribed on the multi-gene bai operon will coincide with the relative abundances of BaiP and BaiJ. As expected, genes for BaiE and BaiCD as well as BaiP and BaiJ were observed to have similar relative frequency (1% and 0.9% of total metagenome assembled genomes (MAGs), respectively). All genes were largely represented by unclassified Firmicutes and *Lachnospiraceae*. (Figure 5a). Representative genera were analyzed to identify candidates which possess multiple genes of the Bai operon which revealed that unclassified Firmicutes, unclassified *Lachnospiraceae*, and *Flavonifractor* harbored all four genes analyzed. This pathway analysis also revealed the novel finding that *Flavonifractor* and *Pseudoflavonifractor* harbor genes for bile acid 7-dehydroxylation. Intriguingly, while bai genes represented approximately 1% of total MAGs, genes were detected in approximately one third of subjects (BaiCD 35%, BaiE 35%, BaiJ 30%, and BaiP 28%). An analysis of differences in gene presence among healthy subjects and those with adenoma and carcinoma revealed that the genes had the greatest abundance in patients with carcinoma, and that the genes baiCD, baiE, and baiJ were significantly associated with carcinoma (Figure 5b, Table S4, S5).

**Discussion**

The results of the current study add to a growing literature demonstrating that the colonic microbes are capable of “resetting” stereochemistry of sterols undergoing enterohepatic circulation through expression of 3α-reductase and 5β-reductase enzymes. So far, two mechanisms have been identified: (1) A direct mechanism whereby bacteria encoding the multi-step bile acid 7α-dehydroxylation pathway convert primary bile acids to either secondary bile acids via BaiCD/BaiN or as shown herein secondary allo-bile acids via BaiP/BaiJ activities; and (2) an indirect mechanism in which certain species of Bacteroidetes convert 5β-secondary bile acids DCA and LCA to 3-oxo-Δ\textsuperscript{4}-intermediates, followed by reduction to secondary allo-bile acids.\textsuperscript{38} The current work is thus a significant advance toward determining the enzymatic basis for the formation of secondary allo-bile acids by the gut microbiome (Figure 6).

Bile acid intermediates in the 7α-dehydroxylation pathway have been determined previously. Björkhem et al.\textsuperscript{51} utilized [3β,\textsuperscript{3}H] [24–\textsuperscript{14}C] and [5β,\textsuperscript{3}H] [24–\textsuperscript{14}C] labeled cholic acid in whole cells and cell extracts of *L. scindens* VPI 12708, observing loss of both 3β- and 5β-hydrogens during conversion of CA to DCA.\textsuperscript{33} Administration of [3β-\textsuperscript{3}H] [24–\textsuperscript{14}C] CA and [5β-\textsuperscript{3}H] [24–\textsuperscript{14}C] CA to volunteers followed by analysis of tritium loss after extraction from duodenal aspirates confirmed that 3-oxo-Δ\textsuperscript{4}-bile acid intermediates were formed during conversion of CA to DCA.\textsuperscript{33} Subsequent work incubating [24–\textsuperscript{14}C] CA with cell extracts of *L. scindens* VPI 12708 revealed a multi-enzyme pathway necessary to convert CA to DCA (and CDCA to LCA).\textsuperscript{52} Hylemon and Björkhem
(1991) isolated nine [24–14C] CA intermediates after incubation with cell-free extracts of CA-induced whole cells of *L. scindens* VPI 12708 providing the biochemical framework to search for enzymes involved in bile acid 7α-dehydroxylations. Subsequent work determined that bile acid 7α-dehydroxylations proceed by two oxidation steps yielding a 7α-hydroxy-3-oxo-Δ4-intermediate, the substrate for the rate-limiting enzyme, bile acid 7α-dehydratase (BaiE). Removal of the C7- hydroxyl yields a 7-deoxy-3-oxo-Δ4-intermediate which is then reduced by flavoproteins BaiN or BaiH to a 7-deoxy-3-oxo-Δ4-intermediate. The BaiCD and BaiA isoforms then convert 7-deoxy-3-oxo-Δ4-intermediates to DCA or LCA. One of the bile acid-inducible [24–14C] CA metabolites identified was [24–14C] allo-LCA, indicating that *L. scindens* possesses an enzyme with bile acid 5α-reductase distinct from BaiCD (bile acid 5β-reductase). The current results establish conclusively that the *baiP* and *baiJ* genes encode bile acid 5α-reductases in different strains of *L. scindens* and related Firmicutes that catalyze the formation of allo-DCA and allo-LCA.

Previous work also demonstrated that BaiA1 and BaiA2 catalyze both the initial oxidation and final reduction in the formation of DCA and LCA. However, a recent report named a gene (*CLOSCI_00522*) adjacent to *baiN*, the “baiO” that encodes a predicted 61 kDa flavin-dependent dehydrogenase proposed to catalyze the final reductive step in the pathway. We tested both BaiA1 and BaiO for reduction of allo-DCA and allo-LCA. While the function of *CLOSCI_00522* in bile acid metabolism remains unclear, our results have extended the functional role of the BaiA1. We determined for the first time that this enzyme converts 3-oxo-allo-DCA and 3-oxo-allo-LCA to allo-DCA and allo-LCA, respectively.

The functional role of the previously reported *baiJKL* operon in *L. scindens* VPI 12708 and *L. hylemonae* DSM 15053 has also been extended by the current study. Ridlon and Hylemon (2012) reported that BaiK and BaiF catalyze bile acid–CoA transferase from secondary bile acids, including allodeoxycholyl–SCoA, to primary bile acids. The *baiJ* gene was annotated as “flavin-dependent fumarate reductase” and “3-ketosteroid-Δ1-dehydrogenase”, and is co-expressed with *baiKL* under the control of the conserved *bai* promoter. We previously observed bile acid induction of *baiJKL* genes by RT-PCR and RNA-Seq in *L. hylemonae* DSM 15053. Also, the *baiJ* gene was reported to be enriched in the gut microbiome in mouse models of liver cancer and CRC. Fecal secondary allo-bile acids have also been reported to be enriched in GI cancers.

Phylogenetic analysis of BaiP from *L. scindens* ATCC 35704 revealed two clusters harboring Firmicutes encoding the *bai* pathway, many of which, such as *P. hiranonis, L. hylemonae*, and strains of *L. scindens*, are known to convert CA and CDCA to DCA and LCA, respectively. These clusters are also represented by taxa such as *Dorea* sp. D27, *P. sphenisci*, and *Oscillospiraceae* MAGs whose genome sequences contain *bai* operons.

Clusters with more distant homologs of BaiP are also worth examining in future studies for novel bile acid 3-oxo-Δ4-reductases. Mining human metagenomic datasets for “core” Bai proteins (BaiCD, BaiE) as well as BaiP and BaiJ sequences confirmed that these enzymes are only encoded in Firmicutes. Roughly a third of healthy, adenoma, and carcinoma subjects had detectable BaiE enzymes representing ~1% of MAGs. A combination of low abundance bile acid 7-dehydroxylating Firmicutes and stringency of the HMM search likely explains the low representation of subjects with detectable Bai enzymes. Intriguingly, and in line with previous reports, Bai enzymes are enriched in CRC subjects relative to healthy subjects.

There is a paucity of studies on secondary allo-bile acids, and the literature which exists is conflicting as to whether to regard these hydrophobic “flat” bile acids as beneficial, disease promoting, or contextually important. Recent work measured the secondary allo-bile acid iso-allo-LCA in fecal samples at an average concentration of ~20 μM, and that low micromolar levels, such as those achieved in our resting cell assays, inhibit the growth of gram-positive pathogens including *Clostridioides difficile* (Figure 6). There is a recent growing interest in the immune mechanisms of action of secondary bile acid derivatives and iso-mer in the colon. Secondary bile acid derivatives, including 3-oxo-DCA, 3-oxo-LCA, iso-DCA (3β, 12α-dihydroxy-5β-cholan-24-oic acid), iso-LCA (3β-hydroxy-5β-cholan-24-oic acid), and certain secondary allo-bile acids (e.g. iso-allo-LCA: 3β-hydroxy-5α-cholan-24-oic acid), regulate the balance of regulatory
T cells (Treg) and pro-inflammatory TH17 cells by promoting expansion of Tregs. The current work is thus an important contribution in a rapidly evolving area of the role of diverse bile acid metabolites generated by the gut microbiome on mechanisms underlying host health and disease.

Materials and methods

Bacterial strains and chemicals

E. coli Top10 [F− mcrA Δ(mrr-hsdRMS-mcrBC) q80lacZΔM15 ΔlacX74 recA1 araD139 Δ(ara-leu) 7697 galU galK rpsL (St3) endA1 nupG] competent cells from Invitrogen (Carlsbad, CA, USA) were used for manipulation of plasmids, and E. coli BL21(DE3) [F−, ompT, hsdSB(rB− mB−), gal, dcm, rne131 (DE3)] was also purchased from Invitrogen and used for protein expression. 3-oxo-Δ4-LCA, 3-oxo-allo-LCA, 3-oxo-LCA, allo-LCA, LCA, and 3-oxo-DCA were purchased from Steraloids (Newport, RI, USA). Isopropyl β-D-1-thiogalactopyranoside (IPTG) was purchased from Gold Biotechnology (St. Louis, MO, USA). All other reagents were of the highest possible purity and purchased from Fisher Scientific (Pittsburgh, PA, USA).

Bile acid synthesis

Authentic 3-oxo-Δ4-DCA and allo-DCA were synthesized as previously described and confirmed by nuclear magnetic resonance (NMR) spectroscopy (Fig. S3, S4).

Cloning of bai operon genes from L. scindens strains

The strains/plasmids, primers, and synthetic DNA sequences used in this study are listed in Table S1, S2, and S3, respectively. First, baiP gene encoding FAD-dependent oxidoreductase and baiA1 gene encoding 3α-HSDH from L. scindens ATCC 35704, baiI gene encoding FAD-dependent oxidoreductase from L. scindens VPI 12708, and baiO encoding a predicted 61 kDa flavin-dependent dehydrogenase were codon-optimized for E. coli and synthesized using gBlocks service from Integrated DNA Technologies (IDT, IA, USA). To construct a BaiP, BaiJ, BaiO or BaiA1 expression plasmid (pBaiP, pBaiA1, pBaiO or pBaiA1), a DNA fragment (vector fraction) was amplified from the pETduet plasmid using a primer pair of V1-F and V1-R, V1-F and V1-R, V1-F and V1-R, or V2-F and V2-R, respectively. Another DNA fragment (insert fraction) was amplified from the synthetic oligomers of BaiP, BaiJ, BaiO or BaiA1 using a primer pair of BaiP-F and BaiP-R, BaiJ-F and BaiJ-R, BaiO-F and BaiO-R or BaiA1-F and BaiA1-R, respectively. The two pairs of PCR products were ligated together by in vitro homologous recombination using a Gibson assembly cloning kit (NEB, Boston, MA, USA), respectively. For construction of a BaiP and BaiA1 co-expression plasmid (pBaiP-A1), a DNA fragment (vector fraction) was amplified from the pBaiP plasmid using a pair of the primers V2-F and V2-R, and another DNA fragment (insert fraction) was amplified from the synthetic oligomer of BaiA1 using a pair of the primers BaiA1-F and BaiA1-R. The two PCR products were ligated together by the Gibson assembly cloning kit (NEB).

Recombinant plasmids (Table S1) were transformed into chemically competent E. coli Top10 cells via heat-shock method, respectively, plated, and grown for overnight at 37°C on lysogeny broth (LB) agar plates supplemented with appropriate antibiotics (Ampicillin: 100 μg/ml). A single colony from each transformation was inoculated into LB medium (5 ml) containing the corresponding antibiotic. The cells were subsequently centrifuged (3,220 × g, 10 min, 4°C) and plasmids were extracted from the cell pallets using QIAprep Spin Miniprep kit (Qiagen, CA, USA). The sequences of the inserts were confirmed by Sanger sequencing (ACGT Inc, Wheeling, IL, USA).

Heterologous expression and purification of Bai enzymes in E. coli

For protein expression, the extracted recombinant plasmids were transformed into E. coli BL21(DE3) cells by use of electroporation method, respectively, and cultured overnight at 37°C on LB agar plates supplemented with appropriate antibiotics. Selected colonies were inoculated into 10 mL of LB medium containing the corresponding antibiotic and grown at 37°C for 6 h with vigorous aeration. The pre-cultures were added to fresh LB medium (1 L), supplemented with appropriate antibiotics, and
aerated at 37°C until reaching an OD<sub>600</sub> (optical density of a sample measured at a wavelength of 600 nm) of 0.3. IPTG was added to each culture at a final concentration of 0.1 mM to induce and the temperature was decreased to 16°C. Following 16 h of culturing, cells were pelleted by centrifugation (4000 × g, 30 min, 4°C) and resuspended in 30 ml of binding buffer (20 mM Tris-HCl, 300 mM NaCl, 10 mM 2-mercaptoethanol, pH 7.9). The cell suspension was subjected to an ultra sonicator (Fisher Scientific) and the cell debris was separated by centrifugation (20,000 × g, 40 min, 4°C).

The recombinant protein in the soluble fraction was then purified using TALON Metal Affinity Resin (Clontech Laboratories, CA, USA) per manufacturer’s protocol. The recombinant protein was eluted using an elution buffer composed of 20 mM Tris-HCl, 300 mM NaCl, 10 mM 2-mercaptoethanol, and 250 mM imidazole at pH 7.9. The resulting purified protein was analyzed using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE).

**Whole cell bile acid conversion assay**

*E. coli* BL21(DE3) strains harboring the constructed plasmids were cultured aerobically at 25°C on LB medium (10 mL) supplementary with appropriate antibiotics and expressed the corresponding proteins by IPTG induction at 25°C. Following 16 h of culturing, the strains were pelleted by centrifugation (3,220 × g, 10 min) and washed twice with anerobic PBS solution. The washed *E. coli* strains were inoculated along with 50 μM bile acid substrates (3-oxo-Δ<sup>4</sup>-LCA, 3-oxo-Δ<sup>4</sup>-DCA, or 3-oxo-allo-LCA) into 10 mL of PBS and incubated anaerobically at room temperature for 12 h. The whole cell reaction cultures were centrifuged at 3,220 × g for 10 min to remove bacterial cells and adjusted the pH of the supernatant to pH 3.0 by adding 25 μL of 2 N HCl. Bile acid metabolites were extracted by vortexing with two volumes of ethyl acetate for 1 to 2 min. The organic layer was recovered and evaporated under nitrogen gas. The products were dissolved in 200 μL methanol and analyzed by liquid chromatography-mass spectrometry (LC-MS).

**Liquid chromatography-mass spectrometry**

LC-MS analysis for all samples was performed using a Waters Acquity UPLC system coupled to a Waters SYNAPT G2 Si ESI mass spectrometer (Milford, MA, USA). For the bile acids as substrates and products of whole cell bioconversion assay by the *E. coli* strains expressing BaiP, Baji, or BaiP-A1 enzymes (3-oxo-Δ<sup>4</sup>-LCA, 3-oxo-Δ<sup>4</sup>-DCA, 3-oxo-LCA, 3-oxo-allo-LCA, 3-oxo-DCA, LCA, allo-LCA, DCA, and allo-DCA) analysis, LC was performed with a Waters Acquity UPLC HSS T3 C18 column (1.8 μm particle size, 2.1 mm × 100 mm) at a column temperature of 40°C. Samples were injected at 0.2 μL. Mobile phase A was a mixture of acetonitrile and methanol (50/50, v/v), and B was 10 mM ammonium acetate. The mobile phase composition was 75% of mobile phase A and 25% of mobile phase B and ran an isocratic mode. The flow rate of the mobile phase was 0.5 mL/min. MS was carried out in negative ion mode with a desolvation temperature of 400°C and desolvation gas flow of 800 L/hr. The capillary voltage was 2,000 V. Source temperature was 120°C, and the cone voltage was 30 V. Chromatographs and mass spectrometry data were analyzed using Waters MassLynx software. Analytes were identified according to their mass and retention time. For quantification of 3-oxo-allo-LCA produced by the *E. coli* BL21 (DE3) expressing BaiP/Baji strains, a standard curve was obtained, and then 3-oxo-allo-LCA was quantified based on the standard curve (Figure S5). The limit of detection (LOD) for 3-oxo-Δ<sup>4</sup>-LCA, 3-oxo-allo-LCA, and allo-LCA was 0.1 μmol/L.

For the cortisol and 11β-OHAD as substrates and products of whole cell bioconversion assay by the *E. coli* strain expressing BaiP enzyme analysis, LC was performed with a Waters Acquity UPLC BEH C18 column (1.7 μm particle size, 2.1 mm × 50 mm) at a column temperature of 40°C. Samples were injected at 0.2 μL. Mobile phase A was a mixture of 95% water, 5% acetonitrile, and 0.1% formic acid, and B was a mixture of 95% acetonitrile, 5% water, and 0.1% formic acid. The mobile phase gradient was as follows: 0 min 100% mobile phase A, 0.5 min 100% A, 6.0 min 30% A, 7.0 min 0% A, 8.1 min 100% A, and 10.0 min 100% A. The flow rate of the mobile phase was 0.5 mL/min. MS was carried out in positive ion mode with
a desolvation temperature of 450°C and desolvation gas flow of 800 L/hr. The capillary voltage was 3,000 V. Source temperature was 120°C, and the cone voltage was 30 V.

**NMR spectroscopy**

To determine the molecular structure of the chemically synthesized 3-oxo-Δ⁴-DCA and allo-DCA at the atomic level, NMR spectroscopy was performed.¹H-NMR spectra were recorded on a JNM-ECA-500 spectrometer (JEOL Co., Tokyo, Japan) at 500 MHz, with pyridine-D₅ as the solvent. Chemical shifts are given as the δ-value with tetramethylsilane (TMS) as an internal standard. The abbreviation used here: s, singlet; d, doublet; bs, broad singlet.

**Phylogenetic analysis**

Sequences for phylogenetic analyses were retrieved from NCBI’s NR protein database using the sequence of HDCHBGLK_03451 as the query and limiting the number of resulting database matches to five thousand and allowing a maximum
The retrieved alignments showed high sequence conservation, therefore the worst E-value seen in the alignments was about 3E-37.

Given the high sequence similarities observed in the search step, sequences were clustered with USEARCH v. 11.0.667 to remove redundancy from the dataset. The cluster_fast command was used with an identity threshold of at least 95% to cluster sequences. Each cluster was represented in the phylogenetic analysis by one representative, the centroid sequence. The only exception was the sequences in the same cluster as the query sequence used above, in which case all sequences from the
Cluster centroids were used in the analysis, instead of just the centroid. Clustering resulted in 1,603 sequences included in the downstream analyses.

Centroids 25% shorter or longer than the average sequence length calculated for the whole dataset (596 amino acids) were removed from the dataset, thus keeping in the analysis only sequences with at least 446 and at most 744 amino acids in length. The 1,460 protein sequences remaining in the dataset were aligned by MUSCLE v. 3.8.1551 and the best-fitting sequence substitution model was identified using ModelTest-NG v. 0.1.7. Phylogenetic
tree inference was performed using the maximum likelihood criterion as implemented by RAxML v. 8.2.12,63 using the WAG sequence substitution model with empirical residue frequencies, gamma-distributed substitution rates, and bootstrap pseudoreplicates (whose number, 250, was determined automatically by the program at run-time). The resulting phylogenetic tree was edited with TreeGraph2 v. 2.15.0–88764 and Dendroscope v. 3.7.665 and further cosmetic adjustments were performed with the Inkscape vector editor (https://inkscape.org/ last accessed on January, 20th, 2022).

Bai gene identification in MAG database

A database of publicly available MAGs from five cohorts varying in CRC status was previously annotated for open reading frames and used for this study.66,67 Custom Hidden Markov Model (HMM) profiles were created for each of the 4 genes of interest (baiCD, baiE, baiP, and baiJ) by creating an alignment of reference protein sequences in this study and blastp results with 60% identity to those reference sequences and then passing the alignments to hmmbuild to create an HMM profile. Initial HMM cutoffs were generated by querying protein sequences from the Human Microbiome Project.66 To further refine HMM profile cutoffs, blast databases were made of each alignment and a concatenated file of predicted open reading frames from the 16,936 MAGs described earlier were queried against the alignment databases. The MAG database was searched using the HMM profiles with finalized cutoffs and hmmscan within HMMER 3.1b2. All custom HMM profiles used for these searches can be found at: https://github.com/escowley/BileAcid_LeeJ.

Summary calculations and statistical analysis for association of Bai genes with disease state from MAG database

Summary calculations of number of gene hits in the MAG database, number of participants with the gene of interest, and disease information were performed in R and can be found in Table S4. Methods for determining associations between Bai genes and disease state were previously described.66 Briefly, chi squared tests were performed on a dataset of binarized participants that were designated as “presence” if any of their MAGs contained a copy of the gene of interest or “absence” if none of their recovered MAGs contained a copy of the gene of interest. P-values less than 0.05 are designated as significant (Table S5).

Acknowledgments

E.S.C. is a Medical Scientist Training Program (MSTP) student and was supported by a National Library of Medicine training grant to the Computation and Informatics in Biology and Medicine Training Program (NLM 5T15LM007359) at UW-Madison, and in part by MSTP grant T32 GM140935. P.G.W. was supported at UI-Chicago by the Cancer Education and Career Development Program grant T32CA057699. L.K.L. was supported by NSF GRFP 2017224867. H.L.D. was supported by the David H. and Norraine A. Baker Graduate Fellowship in Animal Sciences at Illinois.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Funding

This work was supported by National Institutes of Health grants (1R01 CA204808-01 [J.M.R., H.R.G.], R01 GM134423-01A1 [J.M.R.], R03 AI147127-01A1 [J.M.P.A., J.M.R.]) as well as UIUC Department of Animal Sciences Matchstick grant, and Hatch ILLU-538-916.

Data availability statement

The code and HMM profiles used for this study are openly available at: https://github.com/escowley/BileAcid_LeeJ.

References

1. Hofmann AF. The continuing importance of bile acids in liver and intestinal disease. Arch Intern Med. 1999;159 (22):2647–2658. doi:10.1001/archinte.159.22.2647.
2. Midvedt T. Microbial bile acid transformation. Am J Clin Nutr. 1974;27(11):1341–1347. doi:10.1093/ajcn/27.11.1341.
3. Swann JR, Want EJ, Geier FM, Spagou K, Wilson ID, Sidaway JE, Nicholson JK, Holmes E. Systemic gut microbial modulation of bile acid metabolism in host tissue compartments. Proc Natl Acad Sci. 2011;108 (supplement_1):4523–4530. doi:10.1073/pnas.1006734107.
1. Narushima S, Itoha K, Miyamoto Y, Park SH, Nagata K, Kuruma K, Uchida K. Deoxycholic acid formation in gnotobiotic mice associated with human intestinal bacteria. Lipids. 2006;41(9):835–843. doi:10.1007/s11745-006-5038-1.

2. Gustafsson BE, Midvvedt T, Norman A. Metabolism of cholic acid in germfree animals after the establishment in the intestinal tract of deconjugating and 7 alpha-dehydroxylating bacteria. Acta Pathol Microbiol Scand. 1968;72(3):433–443. doi:10.1111/j.1699-0463.1968.tb00457.x.

3. Lan K, Su M, Xie G, Ferslew B C, Brouwer K L, Rajani C, Liu C, Jia W. Key role for the 12-hydroxy group in the negative ion fragmentation of unconjugated C24 bile acids. Anal Chem. 2016;88(14):7041–7048. doi:10.1021/acs.analchem.6b00573.

4. Quinn RA, Melnik AV, Vrbanac A, Fu T, Patras KA, Christy, IK, Bodai, Z, Belda-Ferre, Pedro, Tripathi, Anupriya, Chung, L K, et al. Global chemical effects of the microbiome include new bile-acid conjugations. Nature. 2020;579(7797):123–129 doi:10.1038/s41586-020-2047-9.

5. Zhou H, Hylemon P B. Bile acids are nutrient signaling hormones. Steroids. 2014;86:62–68. doi:10.1016/j.steroids.2014.04.016.

6. Yoshimoto S, Loo TM, Atarashi K, Kanda H, Sato S, Oyadomari S, Iwakura Y, Oshima K, Morita H, Hattori M, et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature. 2013;499(7456):97–101. doi:10.1038/nature12347.

7. Ma C, Han M, Heinrich B, Fu Q, Zhang Q, Sandhu M, Agdashian D, Terabe M, Berzofsky J A, Fako V, et al. Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKTL cells. Science. 2018;360(6391):eaan5931. doi:10.1126/science.aan5931.

8. Ocvirk S, O’Keefe SJ. Influence of bile acids on colorectal cancer risk: potential mechanisms mediated by diet gut microbiota interactions. Current Nutrition Reports. 2017;6(4):315–322. doi:10.1007/s13668-017-0219-5.

9. Chaudhari SN, Harris DA, Aliakbarian H, Luo JN, Henke MT, Subramanian R, Vernon AH, Tavakkoli A, Sheu EG, Devlin AS, et al. Bariatric surgery reveals a gut-restricted TGR5 agonist with anti-diabetic effects. Nat Chem Biol. 2021;17(1):20–29. doi:10.1038/s41589-020-0064-z.

10. Chiang JYL, Ferrell JM. Discovery of farnesoid X receptor and its role in bile acid metabolism. Mol Cell Endocrinol. 2022;548:116168. doi:10.1016/j.mce.2022.111618.

11. Berr F, Kullak-Ublick GA, Paumgartner G, Münzing W, Hylemon PB. 7 alpha-dehydroxylating bacteria enhance deoxycholic acid input and cholesterol saturation of bile in patients with gallstones. Gastroenterology. 1996;111(6):1611–1620. doi:10.1016/S0016-5085(96)70024-0.

12. Wells JE, Berr F, Thomas LA, Dowling RH, Hylemon PB. Isolation and characterization of cholic acid 7alpha-dehydroxylating fecal bacteria from cholesterol gallstone patients. Journal of Hepatology. 2000;32(1):4–10. doi:10.1016/S0168-8278(00)80183-X.

13. Marksteiner J, Blasko I, Kemmler G, Koal T, Humpel C. Bile acid quantification of 20 plasma metabolites identifies lithocholic acid as a putative biomarker in Alzheimer’s disease. Metabolomics. 2018;14(1):1. doi:10.1007/s11306-017-1297-5.

14. MahmoudianDehkordi S, Arnold M, Nho K, Ahmad S, Jia W, Xie G, Louie G, Kueider-Paisley A, Moseley MA, Thompson JW, et al. Altered bile acid profile associated with cognitive impairment in Alzheimer’s disease - an emerging role for gut microbiome. Alzheimers Dement. 2019;15(1):76–92. doi:10.1016/j.jalz.2018.07.217.

15. Porez G, Prawitt J, Gross B, Staels B. Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease. J Lipid Res. 2012;53(9):1723–1737. doi:10.1194/jlr.R024794.

16. Jones, BV, Begley, M, Hill, C, Gahan, CGM, Marchesi, JR. Functional and comparative metagenomic analysis of bile salt hydrolase activity in the human gut microbiome. Proc Natl Acad Sci. 2008;105(36):13580–13585 doi:10.1073/pnas.0804437105.

17. Ridlon, JM, Harris, SC, Bhowmik, S, Kang, D-J, Hylemon, PB. Consequences of bile salt biotransformations by intestinal bacteria. Gut Microbes. 2016;7(1):22–39. doi:10.1002/gtmb.1127483.

18. Kim KH, Park D, Jia B, Baek JH, Hahn Y, Jeon CO. Identification and characterization of major bile acid 7α-dehydroxylating bacteria in the human gut. mSystems. 2022:e0045522.

19. Vital M, Rud T, Rath S, Pieper DH, Schlüter D. Diversity of bacteria exhibiting bile acid-inducible 7α-dehydroxylation genes in the human gut. Comput Struct Biotechnol J. 2019;17:1016–1019. doi:10.1016/j.csbi.2019.07.012.

20. Hale VL, Chen J, Johnson S, Harrington SC, Yab TC, Smyrk TC, Nelson H, Boardman LA, Druliner BR, Levin TR, et al. Shifts in the fecal microbiota associated with adonomasous polyps. Cancer Epidemiol Biomarkers Prev. 2017;26(1):85–94. doi:10.1158/1055-9965.EPI-16-0337.

21. Wirbel J, Pyl PT, Kartal E, Zych K, Kashani A, Milanese A, Fleck JS, Voigt AY, Palleja A, Ponnudurai R, et al. Meta-analysis of fecal metagenomes shows global microbial signatures that are specific for colorectal cancer. Nat Med. 2019;25(4):679–689. doi:10.1038/s41591-019-0406-6.

22. Ochsenkühn T, Bayerdörffer E, Meining A, Schinkel M, Thiede C, Nüssler V, Sackmann M, Hatz R, Neubauer A, Paumgartner G, et al. Colonic mucosal proliferation is related to serum deoxycholic acid levels. Cancer. 1999;85(8):1664–1669. doi:10.1002/(SICI)1097-0142(19990415)85:8<1664::AID-CNCR4>3.0.CO;2-O.

23. van Faassen A, Ochsenkühn T, Houterman S, van der Ploeg EM, Bueno-de-Mesquita BH, Ocké MC, Bayerdörffer E, Janknegt RA. Plasma deoxycholic acid is related to deoxycholic acid in faecal water. Cancer
27. Bayerdörffer E, Mannes GA, Ochsenkühn T, Dirschdel P, Wiebecke B, Paumgartner G. Unconjugated secondary bile acids in the serum of patients with colorectal adenomas. Gut. 1995;36(2):268–273. doi:10.1136/gut.36.2.268.

28. Bayerdörffer E, Mannes GA, Richter Wo, Ochsenkühn T, Wiebecke B, Köpcke W, Paumgartner G. Increased serum deoxycholic acid levels in men with colorectal adenomas. Gastroenterology. 1993;104(1):145–151. doi:10.1016/0016-5085(93)09846-5.

29. Ou J, Carbonero F, Zoetendal EG, Delany JP, Wang M, Newton K, Gaskins HR, O’Keefe SJ. Diet, microbiota, and microbial metabolites in colon cancer risk in rural Africans and African Americans. Am J Clin Nutr. 2013;98(1):111–120. doi:10.3945/ajcn.112.056689.

30. Ocvirk S, Wilson AS, Posma JM, Li JV, Koller KR, Day GM, Flanagan CA, Otto JE, Sacco PE, Sacco FD; Ocvirk S, Wilson AS, Posma JM, Li JV, Koller KR, Day GM, et al. A prospective cohort analysis of gut microbial co-metabolism in Alaska native and rural African people at high and low risk of colorectal cancer. Am J Clin Nutr. 2020;111(2):406–419. doi:10.1093/ajcn/nqz301.

31. Heinken A, Ravcheev D A, Baldini F, Heirendt L, Fleming R M, Thiele I. Systematic assessment of secondary bile acid metabolism in gut microbes reveals distinct metabolic capabilities in inflammatory bowel disease. Microbiome. 2019;7(1):75. doi:10.1186/s40168-019-0689-3.

32. Fiorucci S, Carino, A, Baldoni, M, Santucci, L, Costanzi, E, Graziosi, L, Distrutti, E, Biagioli, M. Bile acid signaling in inflammatory bowel diseases. Dig Dis Sci. 2021;66(3):674–693. doi:10.1007/s10620-020-07675-3.

33. Hylemon PB, Melone PD, Franklund CV, Lund E, Björkhem I. Mechanism of intestinal 7 alpha-dehydroxylation of cholic acid: evidence that alo-deoxycholic acid is an inducible side-product. J Lipid Res. 1991;32(1):89–96. doi:10.1016/S0022-2275(20)42247-3.

34. Bhowmik S, Chiu H-P, Jones DH, Chiu H-J, Miller MD, Xu Q, Farr, C L, Ridlon, J M, Wells, J E, Elsliger, M-A, et al. Structure and functional characterization of a bile acid 7α-dehydratase BaeI in secondary bile acid synthesis. Proteins. 2016;84(3):316–331. doi:10.1002/prot.24971.

35. Funabashi M, Grove TL, Wang M, Varma Y, McFadden ME, Brown LC, Guo C, Higginbottom S, Almo SC, Fischbach MA, et al. A metabolic pathway for bile acid dehydroxylation by the gut microbiome. Nature. 2020;582(7813):566–570. doi:10.1038/s41586-020-2396-4.

36. Tanado T, Kanoh M, Matsumoto M, Sakamoto K, Kamano T. Studies of serum and feces bile acids determination by gas chromatography-mass spectrometry. Rinsho Byori. 2006;54:103–110.

37. Tanado T, Kanoh M, Konoh H, Matsumoto M, Mimura K, Kanoh Y, Sakamoto K, Kamano T. Kinetic analysis of bile acids in the feces of colorectal cancer patients by gas chromatography-mass spectrometry (GC-MS). Rinsho Byori. The Japanese Journal of Clinical Pathology. 2007;55(5):417–427.

38. Sato Y, Atarashi K, Plichtha DR, Arai Y, Sasajima S, Kearney SM, Suda W, Takeda K, Sasaki T, Okamoto S, et al. Novel bile acid biosynthetic pathways are enriched in the microbiome of centenarians. Nature. 2021;599(7885):458–464. doi:10.1038/s41586-021-03832-5.

39. Devendra S, Shrestha R, Alves JMP, Wolf PG, Ly L, Hernandez AG, Méndez-Carcía C, Inboden A, Wiley J, Paul O, et al. Clostridium scindens ATCC 35704: integration of nutritional requirements, the complete genome sequence, and global transcriptional responses to bile acids. Appl Environ Microbiol. 2019;85(7):e0052–19. doi:10.1128/AEM.0052-19.

40. Ridlon, JM, Hylemon, PB. Identification and characterization of two bile acid coenzymes A transferases from Clostridium scindens, a bile acid 7α-dehydroxylating intestinal bacterium. J Lipid Res. 2012;53(1):66–76. doi:10.1194/jlr.M020313.

41. Dawson JA, Mallonee DH, Björkhem I, Hylemon PB. Expression and characterization of a C24 bile acid 7 α-dehydroxylase from Eubacterium sp strain VPI 12708 in Escherichia coli. J Lipid Res. 1996;37(6):1258–1267. doi:10.1016/S0022-2275(20)39155-0.

42. Ridlon JM, Ikegawa S, Alves JM, Zhou B, Kobayashi A, Iida T, Mitamura K, Tanabe G, Serrano M, De Guzman A, et al. Clostridium scindens: a human gut microbe with a high potential to convert glucocorticoids into androgens. J Lipid Res. 2013;54(9):2437–2449. doi:10.1194/jlr.M038869.

43. Devendran, Saravanan, Mythen, SM, Ridlon, JM. The desA and desB genes from Clostridium scindens ATCC 35704 encode steroid 17,20-desmolase. J Lipid Res. 2018;59(6):1005–1014. doi:10.1194/jlr.M083949.

44. Chen X-J, Wang Z-Q, Zhou Z-Y, Zeng N-Y, Huang Q-F, Wang Z-W, Tang W-L, Zhou H-W. Characterization of Peptacetobacter hominis gen. nov., sp. nov., isolated from human faeces, and proposal for the reclassification of Clostridium hiranonis within the genus Peptacetobacter. Int J Syst Evol Microbiol. 2020;70:2988–2997.

45. Wells JE, Hylemon PB. Identification and characterization of a Bile Acid 7α-Dehydroxylation operon in clostridium sp. Strain TO-931, a highly active 7α-dehydroxylating strain isolated from human feces. Appl Environ Microbiol. 2000;66(3):1107–1113. doi:10.1128/AEM.66.3.1107-1113.2000.

46. Ridlon, JM, Kang, D-J, Hylemon, PB. Isolation and characterization of a bile acid inducible 7α-dehydroxylating
55. Song X, Sun X, Oh SF, Wu M, Zhang Y, Zheng W, Geva-Zatorsky N, Jupp R, Mathis D, Benoist C, et al. Microbial bile acid metabolites modulate gut RORγt regulatory T cell homeostasis. Nature. 2020;577 (7790):410–415. doi:10.1038/s41586-019-1865-0.

56. Li W, Hang S, Fang Y, Bae S, Zhang Y, Zhang M, Wang G, McCurry MD, Bae M, Paik D, et al. A bacterial bile acid metabolite modulates Treg activity through the nuclear hormone receptor NR4A1. Cell Host Microbe. 2021;29(1366–77.e9):1366–1377.e9. doi:10.1016/j.chom.2021.07.013.

57. Hang S, Paik D, Yao L, Kim E, Trinath J, Lu J, Ha S, Nelson BN, Kelly SP, Wu L, et al. Bile acid metabolites control TγH17 and Treg cell differentiation. Nature. 2019;576 (7785):143–148. doi:10.1038/s41586-019-1785-z.

58. Leppik RA. Improved synthesis of 3-keto, 4-ene-3-keto, and 4,6-diene-3-keto bile acids. Steroids. 1983;41 (4):475–484. doi:10.1016/0039-128X(83)90087-9.

59. Camacho C, Coulouris G, Avagyan V, Ma N, Papadopoulos J, Bealer K, Madden T L. BLAST+: architecture and applications. BMC Bioinform. 2009;10 (1):421. doi:10.1186/1471-2105-10-421.

60. Edgar RC. Search and clustering orders of magnitude faster than BLAST. Bioinformatics. 2010;26 (19):2460–2461. doi:10.1093/bioinformatics/btq461.

61. Edgar RC. MUSCLE: a multiple sequence alignment method with reduced time and space complexity. BMC Bioinform. 2004;5(1):113. doi:10.1186/1471-2105-5-113.

62. Darriba D, Posada D, Kozlov AM, Stamatakis A, Morel B, Flouri T. ModelTest-NG: a new and scalable tool for the selection of DNA and protein evolutionary models. Mol Biol Evol. 2019;37:291–294. doi:10.1093/molbev/msz189.

63. Stamatakis A. RAxML version 8: a tool for phylogenetic analysis and post-analysis of large phylogenies. Bioinformatics. 2014;30(9):1312–1313. doi:10.1093/bioinformatics/btu033.

64. Stöver BC, Müller KF. TreeGraph 2: combining and visualizing evidence from different phylogenetic analyses. BMC Bioinform. 2010;11:7.

65. Huson DH, Scornavacca C. Dendroscope 3: an interactive tool for rooted phylogenetic trees and networks. Syst Biol. 2012;61(6):1061–1067. doi:10.1093/sysbio/sys062.

66. Wolf PG, Cowley ES, Breister A, Matatov S, Lucio L, Polak P, Ridlon JM, Gaskins HR, Anantharaman K. Diversity and distribution of sulfur metabolic genes in the human gut microbiome and their association with colorectal cancer. Microbiome. 2022;10(1):64. doi:10.1186/s40168-022-01242-x.

67. Pascoli E, Asnicar F, Manara S, Zollo M, Karcher N, Armanini F, Beggini F, Manghi P, Tett A, Ghensi P, et al. Extensive unexplored human microbiome diversity revealed by over 150,000 genomes from metagenomes spanning age, geography, and lifestyle. Cell. 2019;176 (3):649–662.e20. doi:10.1016/j.cell.2019.01.001.